Tafnat 25mg contains Tenofovir Alafenamide is a antiviral medication, which is an nucleotide reverse transcriptase inhibitor active against HBV, Tafnat 25mg in adult is indicated for the treatment of Chronic HBV infection with compensated liver disease. In patient with decompensated cirrhosis using tafnat drug, the safety and efficacy is not established and treatment of HBV infection in such patients is not recommended.
Before the treatment for HIV infection, patients should test for
• treatment of chronic HBV infection
• 25mg administer orally once in a day with food.
In pediatric, safety and efficacy not established <18years of age.
IF OVERDOSE OCCURS: Seek to emergency medical care or call poison control centre immediately. Give all correct information
Tenofovir is a acyclic nucleotide reverse transcriptase inhibitor which fight against viral infection and An prodrug, Phosphonamidate is inactive until Tenofovir is hydrolized in vivo and then phosphorylated to the active metabolite to form Tenofovir diphosphate. Tafnat 25mg Tablet prevents the replication of HIV virus in human cells and then stops the HIV virus from producing new viruses and a novel ester prodrug of the antiretroviral tenofovir ,use to treat HIV infection and chronic hepatitis B.
Tafnat is a phosphonamide prodrug of Tenofovir, peak plasma concentration is approx 0.5hrs after the dose.
Tafnat with a high fat meal increase AUC compared with administration in fasted state.
Plasma protein binding is 80%
Only minimal metabolized by CYP3A
Excreted by kidneys , 32% of dose in feces and<1% excreted in urine. Half life is 0.5hrs
Tafnat 25mg is indicated for the treatment of HIV infections and chronic hepatitis B
Tafnat 25mg with acyclovir,valacyclovir,cidofovir,ganciclovir, aminoglycoside, NSAIAs will cause the Tenofovir concentration and risk of adverse effect increased Tafnat 25mg with lamivudine and Entecavir, telbivudine will cause no possibility of antagonistic antiviral effects against HBV in vitro. When tafnat25mg interact with anticonvulsant drug, antimycobacterial will lead to plasma concentration and AUC is decreased of Tenofovir alafenamide.
Gastrointestinal disorder: diarrhea,vomiting, nausea, abdominal pain, flatulence
General disorder : fatigue
Nervous system: headache, dizziness
Skin and subcutaneous tissue disorders: rash , pruritus
Hepatobiliary disorders: increased ALT
Musculoskeletal and connective tissue disorders: arthralgia
Individual treatment of tenofovir alafenamide should not be used for treatment of HIV infection causes risk of producing of HIV-1 resistance. If patient discontinued of Tenofovir alafenamide drug it will lead to severe acute exacerbation of HBV infection.hence liver function should monitor after several month discontinue of drug. Tafnat with combined with other antiretroviral agaents or alone use will cause lactic acidosis and severe hepatomegaly including fatalities.
Category B : There no sufficient and well – tolerated studies in pregnant women.Tafnat 25mg to be administer only for a limited number of pregnant women, animal reproduction have failed to develop a risk to the fetus. Hence tafnat has no malformation, fetotoxicity or neonatal toxicity during pregnancy.
Limited data used of Tafnat 25MG drug during breastfeeding in HIV infected mothers. Consult doctor before use of drug.
Hypersensitivity to the active ingredients or to any of the products.
Store at cool and dry place
TAFNAT is a film coated tablet store at <300C.
In original container should be store and dispensed
Kept the medicine in a closed container at room temperature. Do not freeze
Discard the medicine after expiry date
Dispose the medicine by taking the advice from healthcare professional.
MISSED DOSE: (If you missed a dose take it as soon as possible, if time reach for next dose, then skip missed dose and continue regular schedule. Do not take extra or 2 dose at a time)